Table 2.

HR (95% CI) of primary outcomes according to TyG index in the four Models

			Model1		Model2		Model3		Model4
Outcomes	TyG groups	Events, n(%)	HR (95% CI)	p Value	HR (95% CI)	p Value	HR (95% CI)	p Value	HR (95% CI)	p Value
All-cause death	T1	45(14.5)	Ref.		Ref.		Ref.		Ref.
	T2	42(13.6)	1.11(0.73–1.69)	0.628	1.04(0.67–1.63)	0.848	1.07(0.68–1.67)	0.765	1.07(0.67–1.1.74)	0.761
	T3	53(16.9)	1.70(1.13–2.57)	0.011	1.75(1.08–2.83)	0.023	1.83(1.12–3.01)	0.015	2.09(1.23–3.55)	0.006
CV death	T1	34(11.0)	Ref.		Ref.		Ref.		Ref.
	T2	28(9.1)	0.97(0.59–1.60)	0.918	0.93(0.55–1.58)	0.801	0.91(0.53–1.56)	0.736	0.93(0.52–1.65)	0.802
	T3	41(13.1)	1.61(1.01–2.58)	0.046	1.89(1.08–3.28)	0.025	1.91(1.08–3.37)	0.026	2.31(1.26–4.24)	0.007
MACCEs	T1	156(51.1)	Ref.		Ref.		Ref.		Ref.
	T2	130(42.3)	1.21(0.91–1.60)	0.186	1.65(1.18–2.30)	0.003	1.64(1.17–2.31)	0.004	1.57(1.11–2.78)	0.023
	T3	157(50.2)	1.32(0.96–1.83)	0.083	1.71(1.15–2.58)	0.008	1.72(1.13–2.62)	0.012	1.83(1.18–3.01)	0.006

CI confidence interval, TyG triglyceride glucose index, HR hazard ratio

Model 1: adjusted for gender, age, body mass index, systolic blood pressure, diastolic blood pressure and heart rate;

Model 2: adjusted for Model 1 + HbA1C, C-creative protein, hematocrit, red blood cell distribution width, BNP, sodium, albumin, creatinine, uric acid, ALB, HDL-C and LVEF;

Model 3: adjusted for Model 2 + history of hypertension, ischemic cardiomyopathy, diabetes mellitus, valvular heart disease, atrial fibrillation and hyperlipidemia;

Model 4: adjusted for Model 3 + use of statins, aldosterone antagonist, digoxin, diuretics, β-Blockers, antiplatelet agent, ACEI/ARB/ARNI, insulin, sodium-glucose contrasporter-2 inhibitor, and metformin